Pitch Competition: Building a Biotech Venture program

Loading Events

web banner

Join us in-person for the Building a Biotech Venture Pitch Competition to learn how the next generation of regenerative and precision medicine researchers are preparing to translate their discoveries toward impact.

Watch as six trainee-led teams from the University of Toronto and its affiliated hospitals pitch their ventures to an expert panel of judges. The winning team will receive $25,000, and the second-place team will receive $10,000 in research funding to advance their product concept.

The competition is the culmination of Medicine by Design’s Building a Biotech Venture program, offered in partnership with the Precision Medicine Initiative (PRiME), Health Innovation Hub (H2i) and Talk Boutique. Over the past several months, teams have worked with mentors to advance early-stage company concepts based on their research and have participated in a series of workshops to develop their business cases.

Come cheer on these up-and-coming entrepreneurs as they showcase their innovative technologies.


William Doo Auditorium

45 Willcocks St, Toronto, ON M5S 2H3

Meet the judges

Meet the teams

CHI Diagnostics

The problem is inflammation.

At CHI Diagnostics, we have developed a blood test that can revolutionize post-transplant care by accurately detecting genetic markers associated with inflammation and identifying which patients are at risk of complications. This empowers us to offer personalized healthcare interventions, minimizing invasive tests for low-risk individuals and ensuring proactive measures for those at higher risk, ultimately optimizing post-transplant outcomes.

Team members: Tafsia Hussain, Filio Billia, John Dick, Sagi Abelson, Fernando Luis Scolari, Jessie Medeiros, Darshan H. Brahmbhatt, Gary Bader


Enhancing the physicians’ MR eyes.

Helixir will use stem cell therapies to treat heart attack to demonstrate that regenerative therapies need the complement of our proprietary delivery technology to enable improved accuracy and increased therapeutic retention. This will then open the door for more minimally invasive regenerative therapies that require our pinpoint treatment delivery system.

Team members: Daniel Djayakarsana, Jaykumar Patel, Moses Cook

NorthMiRs, Inc.

Developing nanotechnology-enables gene therapies to address the underlying immune dysregulation of sepsis.

Sepsis is the most common cause of death in critically ill patients, doctors have to rely on supportive care for these patients as there are no specific treatments addressing the underlying immune dysregulation of the condition. NorthMiRs is changing this standard of care by developing a library of microRNA-based therapies that treats both systemic inflammation and organ-specific dysfunctions to ultimately improve patient outcomes, free up space in the ICU, and reduce the financial burden on the health system.

Team members: Samantha McWhirter, Logan Zettle, Chirag Vaswani, Amin Ektesabi

Re:Pair Genomics

Repairing the “cures”.

We’ve developed AI software to design compact GPS DNAs for gene therapy to make it safe and increase product success in the clinic. What traditionally takes scientists 3-6 months can now be generated within a day. Our innovation holds significant promise for biotech and pharmaceutical firms engaged in gene therapy research and development.

Team members: Luca Hategan, Yosuke Niibori, Shiron Lee, Swapna Prakash

Twenty-nine Therapeutics

Harnessing the power of the copper atom (element 29) to diagnose and treat metastatic disease.

Project Twenty Nine Therapeutics includes the exploration of a promising radiopharmaceutical candidate, Copper 67 (Cu-67), including its various nanomedicine applications. Cu-67 usage is novel and holds potential in theranostics and diagnostic imaging. The project Twenty Nine Therapeutics team is proposing a theranostic pairing of Copper 64 and Copper 67, making this the first combination of these two isotopes in a nanoparticle. The isotope also has unexplored promise in the treatment of various cancers, particularly those that have metastasized to the peritoneal lining. The team is exploring ways to firstly, manufacture and safely ship Cu-67 and secondly, examining its various therapeutic applications.

Team members: Michael Valic, Gang Zheng


A macroporous collagen particle (MCP) based bioink and handheld bioprinter for treating full thickness skin defects.

At Vrit, we’re pioneering a future where autografts are no longer necessary for surgeries. Our handheld bioprinter, part of our broader biomaterials initiative, empowers surgeons to provide advanced care to patients by eliminating the reliance on traditional invasive techniques.

Team members: Sushant Singh, Zhenglin Lu, Michael Li Diao

Share This Story

Go to Top